Skip to main content
      Why are vaccine Abs maintained after CAR-T
      -depletion of pathogenic #Abs are dampened/eliminated
      Clonal repetoire expan

      Janet Pope Janetbirdope

      4 days 20 hours ago
      Why are vaccine Abs maintained after CAR-T -depletion of pathogenic #Abs are dampened/eliminated Clonal repetoire expansion Remission=naive B cell pop'n Reset immune system sparing memory cells vs ?not all pathogenic cells eliminated in tissue #ACR25 @RheumNow @ACRheum #26S21 https://t.co/jb3dD5Ssip
      Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x

      Great discussion by @EBRheum @AkhilSoodMD @Dr_B

      Nouf Al hemmadi NoufAhmedAlham2

      4 days 20 hours ago
      Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD . I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring. @RheumNow #ACR25
      From Fitbit to first diagnosis: AI is rewriting the RA playbook

      Two studies presented at this year’s #ACR25 meeting h

      Dr. John Cush RheumNow

      4 days 20 hours ago
      From Fitbit to first diagnosis: AI is rewriting the RA playbook Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
      New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases

      At #ACR25, the ACR presented new

      Dr. John Cush RheumNow

      4 days 21 hours ago
      New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
      Predicting Rheumatoid Arthritis
      Day 1 Recap: #ACR25 Highlights

      Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they di

      Dr. John Cush RheumNow

      4 days 22 hours ago
      Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th. https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w
      Secukinumab vs Ustekinumab in PsA
      IL-2 Therapy in SLE? Maybe
      CAR T
      Which cells to target
      What patients & what disease
      When is right time
      In vivo (new) ex vivo
      Premeds immune sup

      Janet Pope Janetbirdope

      4 days 23 hours ago
      CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo Premeds immune suppression What to use, ?if anything Cons Is it safe ?long term effectiveness What is failure rate ICANs and other side effects #ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP
      Needle in a haystack
      What T cell to target for #autoimmune diseases

      T cell repetoires (TCR) not all are sequenced and m

      Janet Pope Janetbirdope

      4 days 23 hours ago
      Needle in a haystack What T cell to target for #autoimmune diseases T cell repetoires (TCR) not all are sequenced and many can exist to present antigens Diff scales of approaches Implications CAR-T CD19 CD20 BCMA Treg HLAB27 etc! #ACR25 @ACRheum @RheumNow Alok Joglekar #26S08 https://t.co/Qgw8Akz1xk
      Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC

      TAC+GC was comparable to MMF+GC as continuous induction m

      sheila RHEUMarampa

      4 days 23 hours ago
      Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN. AE rates comparable. TAC - AKI & tremor MMF - leucopenia reassuring data.more tx options. #ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA?

      Pre

      David Liew drdavidliew

      4 days 23 hours ago
      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA? Pretty good so far - but obviously will be under enormous scrutiny when we are looking at diseases with good existing therapies #ACR25 ABST0471 @RheumNow https://t.co/xXyzOwLvx8
      2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1)
      🔹All pts (n=10) met SRI-4 by wk24
      🔹DORIS remission:

      Akhil Sood MD, MS AkhilSoodMD

      4 days 23 hours ago
      2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1) 🔹All pts (n=10) met SRI-4 by wk24 🔹DORIS remission: 5 (wk24), 6 (wk36–48) 🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation 🔹CRS Grade 1 (n=6); no ICANS @RheumNow #ACR25
      ×